251 related articles for article (PubMed ID: 19583834)
21. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis.
Silinsky J; Grimes C; Driscoll T; Green H; Cordova J; Davis NK; Li L; Margolin DA
J Surg Res; 2013 Nov; 185(1):113-8. PubMed ID: 23777983
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
23. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
24. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
25. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
26. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.
Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Waki A; Mori T; Yoshii H; Oh M; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
Nucl Med Biol; 2010 May; 37(4):395-404. PubMed ID: 20447549
[TBL] [Abstract][Full Text] [Related]
27. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
30. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma.
Fan L; He F; Liu H; Zhu J; Liu Y; Yin Z; Wang L; Guo Y; Wang Z; Yan Q; Huang G
BMC Cancer; 2011 Jul; 11():320. PubMed ID: 21798073
[TBL] [Abstract][Full Text] [Related]
31. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
32. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
33. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma.
Shimada M; Sugimoto K; Iwahashi S; Utsunomiya T; Morine Y; Imura S; Ikemoto T
J Gastroenterol; 2010 Aug; 45(8):896-902. PubMed ID: 20379837
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma.
Mansour SF; Atwa MM
Asian Pac J Cancer Prev; 2015; 16(17):7491-6. PubMed ID: 26625750
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
36. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.
Yiming L; Yunshan G; Bo M; Yu Z; Tao W; Gengfang L; Dexian F; Shiqian C; Jianli J; Juan T; Zhinan C
Oncotarget; 2015 Dec; 6(39):42019-27. PubMed ID: 26503471
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
Miller TJ; McCoy MJ; Hemmings C; Bulsara MK; Iacopetta B; Platell CF
Pathology; 2017 Dec; 49(7):721-730. PubMed ID: 29102042
[TBL] [Abstract][Full Text] [Related]
38. Expression of CD133-1 and CD133-2 in ovarian cancer.
Ferrandina G; Bonanno G; Pierelli L; Perillo A; Procoli A; Mariotti A; Corallo M; Martinelli E; Rutella S; Paglia A; Zannoni G; Mancuso S; Scambia G
Int J Gynecol Cancer; 2008; 18(3):506-14. PubMed ID: 17868344
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
40. [Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance].
Zhou L; Wu S; Yu L; Gong X; Song W; Cheng Z
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):196-201. PubMed ID: 25736112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
